Rivaroxaban to treat thrombotic antiphospholipid syndrome

The Lancet Haematology

Volumn 3, Issue 9, 2016, Pages e403-e404

  Urbanus, Rolf T ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; RIVAROXABAN; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; BLOOD LEVEL; HUMAN; NOTE; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS;

ANTIPHOSPHOLIPID SYNDROME; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RIVAROXABAN; THROMBOSIS; WARFARIN;

EID: 84991627503     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(16)30107-7     Document Type: Note

References (8)

1. 1 Miyakis, S, Lockshin, MD, Atsumi, T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006), 295–306.
2. 2 Cervera, R, Piette, JC, Font, J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 46 (2002), 1019–1027.
3. 3 Crowther, MA, Ginsberg, JS, Julian, J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349 (2003), 1133–1138.
4. 4 Finazzi, G, Marchioli, R, Brancaccio, V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 3 (2005), 848–853.
5. 5 Win, K, Rodgers, GM, New oral anticoagulants may not be effective to prevent venous thromboembolism in patients with antiphospholipid syndrome. Am J Hematol, 89, 2014, 1017.
6. 6 Schaefer, JK, McBane, RD, Black, DF, Williams, LN, Moder, KG, Wysokinski, WE, Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: a case series of three patients. Thromb Haemost 112 (2014), 947–950.
7. 7 Cohen, H, Hunt, BJ, Efthymiou, M, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 3 (2016), e426–e436.
8. 8 Pengo, V, Ruffatti, A, Legnani, C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 8 (2010), 237–242.